[HTML][HTML] Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge
DA Stanley, AN Honko, C Asiedu, JC Trefry… - Nature medicine, 2014 - nature.com
Nature medicine, 2014•nature.com
Ebolavirus disease causes high mortality, and the current outbreak has spread unabated
through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus
glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV)
challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5
exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived
replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection …
through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus
glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV)
challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5
exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived
replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection …
Abstract
Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.
nature.com